Maurizio Zangari

High Impact

Professor

University of Arkansas for Medical Sciences

faculty

Internal Med, College of Medicine

69 h-index 512 pubs 19,028 cited

Research Areas

Multiple Myeloma Research and Treatments Cancer-related molecular mechanisms research Immune Response and Inflammation Cancer Treatment and Pharmacology Health disparities and outcomes Microbial infections and disease research Hematopoietic Stem Cell Transplantation

Links

ORCID Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Maurizio Zangari, M.D., is a Professor of Medicine at the University of Arkansas for Medical Sciences (UAMS), specializing in multiple myeloma research. He holds an M.D. from the University of Padua, Italy, and completed his residency in Internal Medicine at Wykoff Heights Medical Center and fellowships in Bone Marrow Transplant and Hematology at Mount Sinai Hospital, both in New York.

Dr. Zangari's research focuses on the molecular and clinical aspects of multiple myeloma. His work has investigated the evolutionary pathways of the disease from smoldering myeloma to relapsed and refractory states, examining its molecular makeup and immune microenvironment at a single-cell level. He has also contributed to understanding the risks and spectrum of infections associated with novel therapies like bispecific antibodies and BCMA-targeting agents in patients with relapsed refractory multiple myeloma. His research has explored geographic and racial disparities in access to advanced therapies such as CAR-T cells and bispecific antibodies for multiple myeloma.

With an h-index of 69, over 512 publications, and more than 19,000 citations, Dr. Zangari is recognized as a highly cited researcher. He leads a research group and collaborates with several colleagues at UAMS, including Sharmilan Thanendrarajan, Carolina Schinke, Frits van Rhee, and Samer Al Hadidi.

Research Overview

Maurizio Zangari, M.D. is a Professor of Medicine with the Myeloma Institute for Research and Therapy at UAMS. Dr. Zangari trained as a fellow in Bone Marrow Transplant and Hematology at Mount Sinai Hospital in New York and a resident in Internal Medicine at Wykoff Heights Medical Center, also in New York. He earned is MD from the University of Padua in Italy. Dr. Zangari was previously at the Myeloma Center from 1998-2007, then left for the University of Utah from 2007-2013. He rejoined the Myeloma Center in 2013 and continues to be greatly involved with clinical trials and research. He is an internationally recognized expert in multiple myeloma with an extensive bibliography of peer-reviewed articles and invited presentations. Dr. Zangari is board certified in Hematology and Internal Medicine. He is a member of the American Society of Hematology.

Metrics

h-index: 69
Publications: 512
Citations: 19,028

Selected Publications

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025) DOI
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025) DOI
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024) DOI
Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study (2024) DOI
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024) DOI
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024) DOI
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab (2024) DOI
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024) DOI
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2024) DOI
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma (2024) DOI
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024) DOI
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024) DOI
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023) DOI
Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study (2023) DOI
Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma (2023) DOI

Research Interests

Hypercoagulability in Cancer Patients. The role of activated protein C in thrombotic manifestation of patients with multiple myeloma. Since the start at the University of Utah I have initiated retrospective and prospective studies of the protein C system function in patients with paraproteinemias and myeloproliferative disorder. I have also continued to test the effect of proteosome inhibition on platelet function. After establishing 5GTM1 C57BL/KaLwRij sub-strain in a pre-clinical model I have tested the function of a proteasome inhibitor through the PTH-PTHR axis. In the last 22 months I focused the research to confirm the hypothesis of the PTH essential role in anti-myeloma proteasome activity testing the effect of PTHR antibodies and the effects of parathyroidectomy. The C57 BLACK MOUSE MODEL will be measured in the presence of different proteasome inhibitors MLN 9708, carfilzomib and CEP 18770. I am the principal investigator in three open investigator-initiated trials (Phase I Exploratory Study of Panobinostat IV in Combination with Relapsed/Refractory Multiple Myeloma Patients; Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients; Bone Effect of Bortezomib in Patients with relapsed/refractory Multiple Myeloma), which focus on the bone anabolic activity of proteasome inhibition to determine the minimal proteosome inhibition associated with the anabolic bone effect in multiple myeloma and to evaluate the effect of proteasome inhibition in smoldering myeloma patients. A phase I study, a combination of two bone anabolic drugs panabinostat (a histone deacetylase inhibitor HDAC) and bortezomib in relapse/refractory multiple myeloma patients.

Grants & Funding

No FP attached Celgene Principal Investigator
No FP attached Ichnos Sciences - Pass Through: Covance Principal Investigator
2005-02 (The CAFÉ Study): CAncer-related Fracture Evaluation - A Multicenter, Prospective, Randomized, Controlled Study to Compare Balloon Kyphoplasty Kyphon, Inc Principal Investigator
UARK 2002-09 Protocol F7SCT-1485, A Multicenter, Randomized, Double Blind, Parallel Groups, Placebo Controlled Trial on Efficacy and Safety of Activat Novo Nordisk Principal Investigator
No FP attached Amgen, Inc. Principal Investigator
MLN 9708 Millennium Pharmaceuticals, Inc. Principal Investigator
No FP attached Novartis Pharmaceuticals Corporation - Pass Through: Dana-Farber/Partners CancerCare, Inc. Principal Investigator
No FP attached Ichnos Sciences - Pass Through: Covance Principal Investigator